133 related articles for article (PubMed ID: 24138433)
1. Notes on testing noninferiority in ordinal data under the parallel groups design.
Lui KJ; Chang KC
J Biopharm Stat; 2013; 23(6):1294-307. PubMed ID: 24138433
[TBL] [Abstract][Full Text] [Related]
2. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
Lode H; Magyar P; Muir JF; Loos U; Kleutgens K;
Clin Microbiol Infect; 2004 Jun; 10(6):512-20. PubMed ID: 15191378
[TBL] [Abstract][Full Text] [Related]
3. Hypothesis testing and estimation in ordinal data under a simple crossover design.
Lui KJ; Chang KC
J Biopharm Stat; 2012; 22(6):1137-47. PubMed ID: 23075013
[TBL] [Abstract][Full Text] [Related]
4. Sample size determination for testing equality in Poisson frequency data under an AB/BA crossover trial.
Lui KJ
Pharm Stat; 2013; 12(2):74-81. PubMed ID: 23364859
[TBL] [Abstract][Full Text] [Related]
5. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
Lui KJ; Chang KC
Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
[TBL] [Abstract][Full Text] [Related]
6. Test equality and sample size calculation based on risk difference in a randomized clinical trial with noncompliance and missing outcomes.
Lui KJ; Chang KC
Biom J; 2008 Apr; 50(2):224-36. PubMed ID: 18264992
[TBL] [Abstract][Full Text] [Related]
7. Test non-inferiority and sample size determination based on the odds ratio under a cluster randomized trial with noncompliance.
Lui KJ; Chang KC
J Biopharm Stat; 2011 Jan; 21(1):94-110. PubMed ID: 21191857
[TBL] [Abstract][Full Text] [Related]
8. Test homogeneity of odds ratio in a randomized clinical trial with noncompliance.
Lui KJ; Chang KC
J Biopharm Stat; 2009 Sep; 19(5):916-32. PubMed ID: 20183452
[TBL] [Abstract][Full Text] [Related]
9. Sample size determination for testing equality in a cluster randomized trial with noncompliance.
Lui KJ; Chang KC
J Biopharm Stat; 2011 Jan; 21(1):1-17. PubMed ID: 21191850
[TBL] [Abstract][Full Text] [Related]
10. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
[TBL] [Abstract][Full Text] [Related]
11. Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.
Hida E; Tango T
J Biopharm Stat; 2013; 23(4):774-89. PubMed ID: 23799810
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
[TBL] [Abstract][Full Text] [Related]
13. Exact sample-size determination in testing non-inferiority under a simple crossover trial.
Lui KJ; Chang KC
Pharm Stat; 2012; 11(2):129-34. PubMed ID: 22232060
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolones in the management of community-acquired pneumonia.
Albertson TE; Dean NC; El Solh AA; Gotfried MH; Kaplan C; Niederman MS
Int J Clin Pract; 2010 Feb; 64(3):378-88. PubMed ID: 20456176
[TBL] [Abstract][Full Text] [Related]
15. Sample size for testing difference between two proportions for the bilateral-sample design.
Qiu SF; Tang NS; Tang ML; Pei YB
J Biopharm Stat; 2009 Sep; 19(5):857-71. PubMed ID: 20183448
[TBL] [Abstract][Full Text] [Related]
16. Testing equality and interval estimation in binary responses when high dose cannot be used first under a three-period crossover design.
Lui KJ; Chang KC
J Biopharm Stat; 2015; 25(1):190-205. PubMed ID: 24836857
[TBL] [Abstract][Full Text] [Related]
17. Sample size determination for testing nonequality under a three-treatment two-period incomplete block crossover trial.
Lui KJ; Chang KC
Biom J; 2015 May; 57(3):410-21. PubMed ID: 25757940
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
[TBL] [Abstract][Full Text] [Related]
19. Testing homogeneity of the risk ratio in stratified noncompliance randomized trials.
Lui KJ
Contemp Clin Trials; 2007 Sep; 28(5):614-25. PubMed ID: 17409026
[TBL] [Abstract][Full Text] [Related]
20. Generalized F test and generalized deviance test in two-way ANOVA models for randomized trials.
Shen J; He X
J Biopharm Stat; 2014; 24(3):523-34. PubMed ID: 24697334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
